Abstract
Introduction: Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barre syndrome characterized by ataxia, areflexia, and ophthalmoplegia. We present a case of MFS following Pfizer COVID-19 vaccine.
Case presentation: A previously healthy 24-year-old female presented with binocular horizontal diplopia 18 days after receiving the first dose of Pfizer COVID-19 vaccine (Comirnaty®). Anti-ganglioside testing revealed positive anti-GQ1b antibodies. Intravenous immunoglobulins were administered, in a dose of 2 g per kg of body weight over 5 days. On a follow-up exam 3 weeks after the treatment, clinical improvement was noted with normal bulbomotor examination.
Conclusion: Patients with acute ophthalmoplegia occurring after COVID-19 vaccination should be screened for the presence of anti-GQ1b antibody. If the antibody is present, intravenous immunoglobulin should be administered as it may hasten clinical improvement.
Keywords: COVID-19; Miller Fisher syndrome; Pfizer vaccine.
【저자키워드】 COVID-19, Miller fisher syndrome, Pfizer vaccine., 【초록키워드】 Treatment, antibodies, Intravenous immunoglobulin, Vaccine, COVID-19 vaccine, antibody, body weight, variant, Pfizer, COVID-19 vaccination, Immunoglobulin, female, Miller fisher syndrome, Clinical improvement, Follow-up, Guillain-barrè syndrome, dose, Diplopia, Ataxia, first dose, positive, Fisher, Fisher syndrome, ophthalmoplegia, Administered, areflexia, horizontal diplopia, Miller, healthy, receiving, screened, characterized, 【제목키워드】 COVID-19 vaccine, Miller fisher syndrome,